Genmab A (GMAB) EBITDA (2018 - 2026)

Genmab A (GMAB) has reported EBITDA for 9 consecutive years, with $375.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 31.57% year-over-year to $375.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.1 billion (up 35.99% YoY), and the FY2025 full-year result was $1.1 billion, up 70.77% from the prior year.
• EBITDA improved to $375.0 million in Q2 2026 per GMAB's latest filing, from $180.0 million in the prior quarter.
• Across five years, EBITDA topped out at $1.7 billion in Q3 2023 and bottomed at -$2.9 billion in Q4 2023.
• Historically, EBITDA has averaged $166.6 million across 5 years, with a median of $180.0 million in 2026.
• The sharpest annual moves came in 2024 and 2025: EBITDA plunged 61.44% in 2024, then surged 256.93% in 2025.
• Over 5 years, EBITDA stood at $127.1 million in 2022, then sank by 2364.72% to -$2.9 billion in 2023, then soared by 122.99% to $662.0 million in 2024, then jumped by 52.11% to $1.0 billion in 2025, then plunged by 62.76% to $375.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $375.0 million, $180.0 million, and $1.0 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.